Communicating emerging safety risks of marketed medicines

Eu2P Short Course: Communicating emerging safety risks of marketed medicines

OBJECTIVES

This course aims to provide you knowledge and understanding of the challenges met by regulatory agencies in risk communication.

Risk communication, DHCP, pattern of drug, medicines

At the end of the course, you will be able to:

understand how the impact of DHCP on patterns of drug use can be evaluated and the potential determinates (both DHCP & drug) of that impact

Dr. Paul Benkimoun

Université de Bordeaux

Dr. Peter Mol

Principal Assessor of Pharmacotherapy Group II; cardiovascular, diabetes and female hormone products
Dutch Medicines evaluation Board

BROWSE BY DOMAIN

Short courses can be included in a training package for your team!

Monday-Friday / 9.00am-6.00pm CET